Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mexiletine - Boehringer Ingelheim

Drug Profile

Mexiletine - Boehringer Ingelheim

Alternative Names: Mexiletine hydrochloride; Mexitil; Mexitilen

Latest Information Update: 28 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Class Ib antiarrhythmics; Local anaesthetics; Phenyl ethers; Propylamines; Small molecules
  • Mechanism of Action Neuromuscular blocking agents; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arrhythmias; Diabetic neuropathies
  • No development reported Peripheral nervous system diseases; Torticollis

Most Recent Events

  • 20 Oct 2003 A clinical study has been added to the pharmacokinetics section
  • 15 Dec 2000 Investigation in Torticollis in Italy (Unknown route)
  • 21 Jul 2000 Launched for Diabetic neuropathies in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top